Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial

Friedman, 2018, Mechanisms of NAFLD development and therapeutic strategies, Nat Med, 24, 908, 10.1038/s41591-018-0104-9 Tillman, 2020, FGF21: An emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases, Front Endocrinol, 11, 10.3389/fendo.2020.601290 Chalasani, 2018, The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases, Hepatology, 67, 328, 10.1002/hep.29367 Lebeaupin, 2018, Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease, J Hepatol, 69, 927, 10.1016/j.jhep.2018.06.008 Bril, 2017, Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease, Hepatology, 65, 1132, 10.1002/hep.28985 Younossi, 2018, Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention, Nat Rev Gastroenterol Hepatol, 15, 11, 10.1038/nrgastro.2017.109 Fon Tacer, 2010, Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse, Mol Endocrinol, 24, 2050, 10.1210/me.2010-0142 Kharitonenkov, 2017, Fibroblast growth factor 21 night watch: advances and uncertainties in the field, J Intern Med, 281, 233, 10.1111/joim.12580 Chau, 2010, Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1α pathway, Proc Natl Acad Sci USA, 107, 12553, 10.1073/pnas.1006962107 Chen, 2017, Fasting-induced hormonal regulation of lysosomal function, Cell Res, 27, 748, 10.1038/cr.2017.45 Stanislaus, 2017, A novel Fc-FGF21 with improved resistance to proteolysis, increased affinity toward β-klotho, and enhanced efficacy in mice and cynomolgus monkeys, Endocrinology, 158, 1314, 10.1210/en.2016-1917 Kaufman, 2020, AKR-001, an Fc-FGF21 analog, showed sustained pharmacodynamic effects on insulin sensitivity and lipid metabolism in type 2 diabetes patients, Cell Rep Med, 1 Harrison, 2021, Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial, Nat Med, 27, 1262, 10.1038/s41591-021-01425-3 Harrison, 2022, A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis, HEP Rep, 5 Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 Szulc, 2018, Bone turnover: Biology and assessment tools, Best Pract Res Clin Endocrinol Metab, 32, 725, 10.1016/j.beem.2018.05.003 Mak, 2021, Systematic review with meta-analysis: diagnostic accuracy of Pro-C3 for hepatic fibrosis in patients with non-alcoholic fatty liver disease, Biomedicines, 9, 10.3390/biomedicines9121920 Luo, 2018, An evaluation of the collagen fragments related to fibrogenesis and fibrolysis in nonalcoholic steatohepatitis, Sci Rep, 8, 10.1038/s41598-018-30457-y Harrison, 2021, Efruxifermin (EFX) improved markers of fibrosis, liver injury and metabolism in F4 NASH patients with compensated cirrhosis, J Hepatol, 75, S204 Lambert, 2014, Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease, Gastroenterology, 146, 726, 10.1053/j.gastro.2013.11.049 Yoneda, 2022, Combination of tofogliflozin and pioglitazone for NAFLD: extension to the ToPiND randomized controlled trial, Hepatol Commun, 6, 2273, 10.1002/hep4.1993 Romero-Gómez, 2023, A phase 2a active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with nonalcoholic fatty liver disease, J Hepatol, 10.1016/j.jhep.2023.05.013 Meng, 2021, FGF21 ameliorates hepatic fibrosis by multiple mechanisms, Mol Biol Rep, 48, 7153, 10.1007/s11033-021-06707-0 Matchett, 2023, Multimodal decoding of human liver regeneration, bioRxiv Vilar-Gomez, 2015, Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis, Gastroenterology, 149, 367, 10.1053/j.gastro.2015.04.005 Lassailly, 2020, Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis, Gastroenterology, 159, 1290, 10.1053/j.gastro.2020.06.006 Francque, 2021, A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH, N Engl J Med, 385, 1547, 10.1056/NEJMoa2036205 Harrison, 2019, Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, Lancet, 394, 2012, 10.1016/S0140-6736(19)32517-6 Newsome, 2021, A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis, N Engl J Med, 384, 1113, 10.1056/NEJMoa2028395 Brown, 2023, Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial, JHEP Rep Innov Hepatol, 5 Loomba, 2023, Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH, N Engl J Med, 10.1056/NEJMoa2304286 Esan, 2021, Triglycerides and cardiovascular disease, Curr Opin Cardiol, 36, 469, 10.1097/HCO.0000000000000862 Cusi, 2022, Endocr Pract, 28, 528, 10.1016/j.eprac.2022.03.010 Sanyal, 2019, Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial, Lancet, 392, 2705, 10.1016/S0140-6736(18)31785-9 Targher, 2007, Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease, Nutr Metab Cardiovasc Dis, 17, 517, 10.1016/j.numecd.2006.04.002